| abstract |
The invention relates to a novel therapeutic application of alpha- [10-oxy-4H-benzo [4,5] cyclohepta [1,2-b] thiophene-4-ylidene] -carboxylic acids, their physiologically hydrolyzable and physiologically acceptable esters. and pharmaceutically acceptable salts thereof as monokine inhibitory agents, particularly as inhibitors of secretion or release of interleukin-1 for therapeutic treatment other than anti-inflammatory or anti-pyretic treatment. |